MI-EATON
6.9.2022 12:31:56 CEST | Business Wire | Press release
Power management company Eaton will display its Vehicle Group's innovative portfolio of internal combustion solutions for commercial vehicles Sept. 20-25 at the IAA Transportation show in Hannover, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005013/en/
Eaton’s Vehicle Group offers a portfolio of technologies that reduce emissions and improve fuel economy in commercial vehicles today and well into the future. (Photo: Business Wire)
"Although the transition to electrification is progressing, OEMs continue to seek improvements in fuel emissions and consumption for internal combustion engines," said Traci Melville, senior vice president and general manager, Global Products, Eaton's Vehicle Group. "In fact, according to KGP Powertrain Intelligence, there will be more than 30 million commercial vehicles produced with a diesel engine over the next decade."
Variable Valve Actuation technologies are flexible, reduce emissions
Eaton's Variable Valve Actuation (VVA) solutions are flexible and adaptable to any valvetrain architecture, allowing OEM customers to implement one or multiple functions that can significantly reduce carbon dioxide (CO2) and nitrogen oxides (NOx) emissions and lower fuel use.
Cylinder deactivation keeps selective catalytic reduction (SCR) at optimal temperatures by operating just two or three cylinders rather than all six in light-load conditions. That effectively delivers higher exhaust temperatures from the functioning cylinders at low speeds and loads or when the truck is neutral coasting, two conditions that can quickly cool aftertreatment systems. Concurrently, cylinder deactivation also lowers fuel consumption.
Late intake valve closing improves the engine's thermal efficiency, enabling a higher compression ratio, which reduces CO2 emissions and increases exhaust gas temperature that contributes to aftertreatment performance.
TVS EGR pump more controllable than competitive offerings
Eaton's positive-displacement TVS® exhaust gas recirculation (EGR) pump enables the use of a high-efficiency turbo to reduce engine pumping losses and increase fuel economy. The TVS® EGR pump is driven by a 48-volt electric motor, making it completely independent from engine speed and significantly more controllable than pumpless EGR systems.
Decompression engine brake compact, integrates into small engines
Eaton's decompression engine brake technology enhances brake power in the full engine operating range and is compact for easy integration into smaller engines.
Eaton's engine decompression brake is a valvetrain system with a mechanism to quickly switch between driving and engine braking mode according to customer requirements and can be integrated into a standard assembly.
Eaton's valves operate in demanding engine applications
Eaton offers a portfolio of differing valves, including monometallic and bimetallic, solid and hollow sodium cooled, seat faced and coated, providing a suitable solution for all vehicle applications. Eaton is developing new valve technologies for future commercial vehicles, including those with hydrogen internal combustion engines (ICE). Unlike traditional diesel-powered commercial vehicle engines, hydrogen ICE powertrains can operate dry combustion at extremely elevated temperatures depending on engine calibration.
Eaton is leveraging its nearly 100 years of experience in valve production to support hydrogen applications and the next generation of diesel engines. One possible solution is a sodium-filled hollow valve, which enables internal cooling. Wear protection is ensured by selecting the proper materials and coatings among the several grades available in Eaton's portfolio.
Eaton, Tenneco offer exhaust thermal management system to reduce emissions
Eaton and Tenneco launched a joint development agreement between Eaton's Vehicle Group and Tenneco's Clean Air business to produce an integrated exhaust thermal management system that enables commercial truck manufacturers to meet upcoming emissions regulations.
The integrated exhaust thermal management system provides heat directly to the vehicle's aftertreatment system, which is essential for reducing harmful exhaust emissions. Eaton's electrically driven TVS® blower precisely controls the airflow so the system can maintain optimal aftertreatment temperatures.
48-volt electric catalyst heater controller provides precise aftertreatment control
Eaton offers an air-cooled electric catalyst heater controller as part of its broader 48-volt electrical system portfolio. It contains several technologies that allow manufacturers to integrate 48-volt architectures into next-generation commercial vehicles. The controller manages the power delivered to the aftertreatment heater and is designed to receive commands from the aftertreatment system and provide soft-start and soft-stop capabilities for maintaining system voltage control.
48-volt DC-DC Converter for dual-voltage electrical systems
Eaton is developing a DC-DC Converter for 48V system architectures that will enable future powertrains to comply with new emissions regulations and provide higher levels of electrical power for CO2 reduction and autonomous driving systems. Unlike competitive offerings, Eaton's DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.
Supercapacitors for 48-volt system power storage
Eaton has a current portfolio of supercapacitors for use in commercial vehicle applications, including 48V commercial vehicle systems. In addition, Eaton is developing advanced technology to further increase the level of power and energy storage capacity in these products.
Supercapacitors can quickly charge and discharge at higher rates than lithium-ion batteries. While the size and weight are comparable to lithium-ion packs, supercapacitors don't retain high levels of energy in comparison, do not require a liquid cooling system and have a longer cycle life.
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, to operate sustainably and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet's transition to renewable energy, helping to solve the world's most urgent power management challenges, and doing what's best for its stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005013/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
